To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults

Summary

The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.

Eligibility

Inclusion Criteria:

* Signed informed consent
* Age: 19 and over , healthy volunteer
* Body mass index (BMI): 18.5≤BMI≤29.9 kg/m²

Exclusion Criteria:

* Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination or effects of the study drugs will not be normal
* Clinically relevant findings(e.g. blood pressure, electrocardiogram(ECG); physical and gynecological examination, laboratory examination)

Conditions3

Interventions3

Related trials

• Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes — Karolinska Institutet
• EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease — National Taiwan University Hospital
• Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus — Medanta, The Medicity, India
• Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia — University Hospital, Basel, Switzerland
• Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease — National Taiwan University Hospital
• SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan — The University of Texas Health Science Center at San Antonio
• SGLT2i, Hepatic Glucose Production, and SNS — The University of Texas Health Science Center at San Antonio
• SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia — The University of Texas Health Science Center at San Antonio

Browse More Trials